Kane Biotech Inc (TSE:KNE)
:KNE
Want to see TSE:KNE full AI Analyst Report?
Total Valuation
Kane Biotech has a market cap or net worth of C$6.36M. The enterprise value is C$7.77M.
Market CapC$6.36M
Enterprise ValueC$7.77M
Share Statistics
Kane Biotech has 181,856,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding181,856,570
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kane Biotech’s return on equity (ROE) is 3.65 and return on invested capital (ROIC) is -192.17%.
Return on Equity (ROE)3.65
Return on Assets (ROA)-1.00
Return on Invested Capital (ROIC)-192.17%
Return on Capital Employed (ROCE)-13.41
Revenue Per Employee13.37K
Profits Per Employee-85.04K
Employee Count32
Asset Turnover0.16
Inventory Turnover1.17
Valuation Ratios
The current PE Ratio of Kane Biotech is ―. Kane Biotech’s PEG ratio is 0.09.
PE Ratio―
PS Ratio15.17
PB Ratio-8.69
Price to Fair Value-8.69
Price to FCF-1.99
Price to Operating Cash Flow-1.74
PEG Ratio0.09
Income Statement
In the last 12 months, Kane Biotech had revenue of 427.87K and earned -2.72M in profits. Earnings per share was -0.02.
Revenue427.87K
Gross Profit-163.38K
Operating Income-3.11M
Pretax Income-2.83M
Net Income-2.72M
EBITDA-2.95M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -3.26M and capital expenditures -4.89K, giving a free cash flow of -3.26M billion.
Operating Cash Flow-3.26M
Free Cash Flow-3.26M
Free Cash Flow per Share-0.02
Dividends & Yields
Kane Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change-56.25%
50-Day Moving Average0.04
200-Day Moving Average0.04
Relative Strength Index (RSI)44.48
Average Volume (3m)112.95K
Important Dates
Kane Biotech upcoming earnings date is May 21, 2026, TBA (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateMay 21, 2026
Ex-Dividend Date―
Financial Position
Kane Biotech as a current ratio of 0.68, with Debt / Equity ratio of -308.66%
Current Ratio0.68
Quick Ratio0.47
Debt to Market Cap0.30
Net Debt to EBITDA-0.48
Interest Coverage Ratio-12.82
Taxes
In the past 12 months, Kane Biotech has paid -108.00K in taxes.
Income Tax-108.00K
Effective Tax Rate0.04
Enterprise Valuation
Kane Biotech EV to EBITDA ratio is -2.68, with an EV/FCF ratio of -2.42.
EV to Sales18.44
EV to EBITDA-2.68
EV to Free Cash Flow-2.42
EV to Operating Cash Flow-2.42
Balance Sheet
Kane Biotech has C$901.70K in cash and marketable securities with C$2.30M in debt, giving a net cash position of -C$1.40M billion.
Cash & Marketable SecuritiesC$901.70K
Total DebtC$2.30M
Net Cash-C$1.40M
Net Cash Per Share>-C$0.01
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is -38.18%, with operating margin of -727.40%, and net profit margin of -636.00%.
Gross Margin-38.18%
Operating Margin-727.40%
Pretax Margin-661.24%
Net Profit Margin-636.00%
EBITDA Margin-689.37%
EBIT Margin-727.40%
Analyst Forecast
The average price target for Kane Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―